Nephrogenic systemic fibrosis: Center case review

Journal of Magnetic Resonance Imaging

Volumn 26, Issue 5, 2007, Pages 1198-1203

  Lauenstein, Thomas C ^a   Salman, Khalil ^a   Morreira, Roger ^a   Tata, Sudha ^a   Tudorascu, Dana ^a   Baramidze, George ^a   Singh Parker, Sareeta ^a   Martin, Diego R ^a,b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY CLINIC   (United States)

Author keywords

Acidosis; Cofactors; Dialysis; Gadodiamide; Impaired renal function; Nephrogenic systemic fibrosis (NSF)

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOXETIC ACID; PHOSPHORUS;

ADOLESCENT; ADULT; AGED; ANION GAP; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MALE; MEDICAL RECORD; NEPHROGENIC FIBROSING DERMOPATHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC DISEASE;

ADOLESCENT; ADULT; AGED; COHORT STUDIES; COMORBIDITY; CONTRAST MEDIA; FEMALE; FIBROSIS; GADOLINIUM; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES;

EID: 35848946598     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.21136     Document Type: Article

References (29)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1001.
2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-393.
3. Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 2006;130:209-212.
4. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis 2005;46:754-759.
5. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic: fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42: 139-145.
6. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928-930.
7. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790.
8. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 2003;25:358.
9. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48:55-60.
10. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
11. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359-2362.
12. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243:148-157.
13. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188: 586-592.
14. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27-30.
15. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
16. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21-26.
17. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006;19:191-194.
18. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6:2212-2217.
19. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera Velazquez S, Jimenez SA. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006; 35:238-249.
20. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647-649.
21. Bayer Healthcare Pharmaceuticals. Magnevist Safety Information. Available at: http://www.imaging.bayerhealthcare.com/html/ magnevist/nsf_nfd.html?WT. mc_id=berleximaging.com. Last accessed: August 14, 2007.
22. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20:563-576.
23. Aydingoz U. The need for radiologists' awareness of nephrogenic systemic fibrosis. Diagn Interv Radiol 2006;12:161-162.
24. International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR). Home page. Available at: http://www.icnfdr.org. Last accessed: August 14, 2007.
25. Thomsen HS. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007;17:70-76.
26. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006;8:151-157.
27. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614-617.
28. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003;25:204-209.
29. Swaminathan S, Ahmed I, McCarthy JT, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006;145:234-235.